Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria

22 maj 2026 uppdaterad av: Chengdu Suncadia Medicine Co., Ltd.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HRS-3095 in Patients With Chronic Spontaneous Urticaria

The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Interventionell

Inskrivning (Beräknad)

190

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200040
        • Huashan Hospital Affiliated to Fudan University
        • Huvudutredare:
          • Wenyu Wu
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310006
        • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
        • Huvudutredare:
          • Liming Wu
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Participants must be between 18 and 70 years of age, inclusive, at the time of signing the Informed Consent Form (ICF), with no restriction on gender.
  2. Participants must have a history of chronic spontaneous urticaria (CSU) with a disease duration of at least 6 months prior to screening.
  3. Participants must be diagnosed with H1-antihistamine-inadequately-controlled CSU at screening, defined as: having had persistent symptoms of pruritus and wheals for ≥6 weeks prior to screening, despite regular use of second-generation H1-antihistamines during that period.
  4. At randomization, the UAS7 score must be ≥16 (range: 0-42) and the HSS7 score ≥ 8 (range: 0-21).
  5. Participants must have been on a stable dose of the specified second-generation H1-antihistamine for at least 3 days prior to the first UAS score at screening.
  6. Participants must be willing and able to complete logbook entries as required during the study and must have no missing daily UAS scores during the 7 days before randomization.
  7. Participants must voluntarily sign the Informed Consent Form (ICF) before any study-related procedures, be able to communicate effectively with the investigator, and be willing to strictly adhere to the requirements of the study protocol.
  8. Female participants of childbearing potential or male participants with a female partner of childbearing potential must agree to avoid donating sperm or ova and must agree to take highly effective contraceptive measures from the time of signing the ICF until 3 months after the last dose.

Exclusion Criteria:

  1. Any skin disease that could interfere with study assessment (e.g., chronic inducible urticaria, urticarial vasculitis, atopic dermatitis, psoriasis).
  2. Use of systemic or topical medications with therapeutic or immunomodulatory effects on the study disease during the relevant washout period prior to screening.
  3. Use of investigational drugs or medical devices within 8 weeks or 5 half-lives (if known), whichever is longer, or within 30 days (for small molecules) prior to screening.
  4. Vaccination or exposure to live or attenuated vaccines within 3 months prior to screening or participation in a vaccine-related clinical trial within 3 months prior to randomization.
  5. History or current coagulation-related risk (e.g., bleeding diathesis, coagulopathy, GI bleeding with clinical significance, antiplatelet or anticoagulant use, history of thrombosis or thromboembolic events, or increased risk of thrombosis).
  6. History of liver disease or current treatment for liver disease (e.g., hepatitis, cirrhosis, liver failure).
  7. History of systemic antimicrobial use or presence of superficial skin infection (e.g., impetigo) within 4 weeks prior to screening.
  8. History of malignancy or current malignancy (excluding completely resected and recurrence-free basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia).
  9. Major surgery performed within 3 months prior to randomization or planned during the study.
  10. Serious concomitant disease or any condition judged by the investigator to make the participant unsuitable for study participation.
  11. Abnormal findings in vital signs, physical examination, laboratory tests, ECG, chest X-ray/CT, or abdominal ultrasound during screening that have clinical significance and may affect study validity or participant safety.
  12. Pregnant or breastfeeding women.
  13. Allergy to the study drug or any of its components.
  14. History of alcohol abuse within 6 months prior to screening (e.g., > 14 units/week) or history of illicit drug abuse within 6 months prior to screening.
  15. Any condition judged by the investigator that may affect the safety or efficacy evaluation of the study drug or participant compliance with the study procedures or diary.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: HRS-3095 Group
HRS-3095 in different doses.
HRS-3095 tablet.
Placebo-jämförare: HRS-3095 placebo Group
HRS-3095 blank preparation.
HRS-3095 tablet placebo.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 4.
Tidsram: Up to 4 weeks.
Up to 4 weeks.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The concentration of HRS-3095 in serum (Cmax)
Tidsram: From the beginning of administration to the 4th week.
From the beginning of administration to the 4th week.
The time of metabolism of the drug in the serum
Tidsram: From the beginning of administration to the 4th week.
The concentration of HRS-3095 in plasma will be determined.
From the beginning of administration to the 4th week.
The concentration of HRS-3095 in serum (AUC)
Tidsram: From the beginning of administration to the 4th week.
The concentration of HRS-3095 in plasma will be determined.
From the beginning of administration to the 4th week.
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Percentage change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Percentage change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Percentage change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Proportion of patients with UAS7 ≤ 6 at Week 2 and 4 compared to baseline
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Proportion of patients with UAS7 = 0 at Week 2 and 4 compared to baseline
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Proportion of patients achieving the Minimum Important Difference (MID) in UAS7 at Week 2 and 4
Tidsram: Up to 4 weeks.
≥ 10-point decrease from baseline.
Up to 4 weeks.
Proportion of patients achieving the Minimum Important Difference (MID) in ISS7 at Week 2 and 4
Tidsram: Up to 4 weeks.
≥ 5-point decrease from baseline.
Up to 4 weeks.
Time to achieve the Minimum Important Difference (MID) in UAS7
Tidsram: Up to 4 weeks.
≥ 10-point decrease from baseline.
Up to 4 weeks.
Time to achieve the Minimum Important Difference (MID) in ISS7
Tidsram: Up to 4 weeks.
≥ 10-point decrease from baseline.
Up to 4 weeks.
Change in 7-day Angioedema Activity Score (AAS7) from baseline at Week 2 and 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Change in Urticaria Control Test (UCT) from baseline at Week 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Proportion of participants with UCT ≥ 12 at Week 4 compared to baseline
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Change in Dermatology Life Quality Index (DLQI) from baseline at Week 4
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Proportion of participants with DLQI = 0 or 1 at Week 4 compared to baseline
Tidsram: Up to 4 weeks.
Up to 4 weeks.
Adverse events
Tidsram: From the beginning of administration to the 8th week.
From the beginning of administration to the 8th week.
Plasma concentrations of HRS-3095 and its metabolites
Tidsram: From the beginning of administration to the 4th week.
From the beginning of administration to the 4th week.
Relative change from baseline in serum total immunoglobulin E (IgE)
Tidsram: From the beginning of administration to the 4th week.
From the beginning of administration to the 4th week.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2026

Primärt slutförande (Beräknad)

1 december 2026

Avslutad studie (Beräknad)

1 mars 2027

Studieregistreringsdatum

Först inskickad

22 maj 2026

Först inskickad som uppfyllde QC-kriterierna

22 maj 2026

Första postat (Faktisk)

29 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera